Zai Lab Ltd. (ADRs) (1ZL.SG)
| Previous Close | 36.80 |
| Open | 35.80 |
| Bid | 36.40 x 0 |
| Ask | 36.80 x 0 |
| Day's Range | 35.80 - 35.80 |
| 52 Week Range | 21.40 - 51.50 |
| Volume | |
| Avg. Volume | 19 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Zai Lab Announces Participation in February Investor Conferences
SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023: Guggenheim Oncology ConferenceFireside Chat: Wednesday, February 8, 2023, 3:20 p.m. ESTLocation: New York SVB Securities Global Biopharma ConferenceFireside Chat: Tuesday, February 14, 2023, 8:00 a.m. EST Citi Biotech C-Suite Fireside Chat SeriesFir
- GlobeNewswire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
SHANGHAI and CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR) for the treatment of infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapenem-resistant (CRAB) strains. “The CDE’s decision to grant pri
- GlobeNewswire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
SHANGHAI and CAMBRIDGE, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include both QINLOCK® (ripretinib) for advanced gastrointestinal stromal tumor (GIST) patients who have received prior treatment with three or more kina
